Advicenne

The Board of Directors has elected Dr. André Ulmann, current Board Observer of the company, as Interim CEO of Advicenne, with immediate effect.

Dr. André Ulmann has over thirty years’ experience as a Pharmaceutical Industry executive in various positions. André joined Roussel Uclaf (later Sanofi Aventis) where he led R&D in endocrinology and neurology. In 1996, he created and led HRA Pharma for more than 20 years, a company specialized in women’s health and rare diseases and oncology. He grew the company from inception to more than €100m sales in 2017. In 1999, HRA Pharma launched Norlevo, better known as the “morning-after pill”. Norlevo is now available in more than fifty countries and HRA Pharma is considered a pioneer in emergency contraception. The company was acquired in 2016 in a major Private Equity transaction. Andre also serves on Asarina (Stockolm : ASAP.ST) and has served on Advicenne board since 2008. In 2018, André was the recipient of the First John Baxter award for Entrepreneurship given by the American Endocrine Society. Dr. Ulmann is a Doctor of Medicine and Doctor of Science from the University of Paris, and began his career practicing Nephrology at Hôpital Necker (Paris, France), where he was responsible for the care of cystinuria patients.

Org chart

Teams

Leadership Team

Offices